Your browser is no longer supported. Please, upgrade your browser.
Petros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.81 Insider Own36.74% Shs Outstand9.80M Perf Week-21.43%
Market Cap17.77M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.21M Perf Month-16.14%
Income-7.80M PEG- EPS next Q- Inst Own9.90% Short Float2.35% Perf Quarter-45.95%
Sales12.90M P/S1.38 EPS this Y36.70% Inst Trans-19.58% Short Ratio1.83 Perf Half Y-41.74%
Book/sh1.99 P/B0.94 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh1.16 P/C1.62 EPS next 5Y- ROE- 52W Range1.80 - 5.96 Perf YTD-57.50%
Dividend- P/FCF- EPS past 5Y- ROI-64.20% 52W High-68.62% Beta-
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin70.90% 52W Low3.89% ATR0.20
Employees27 Current Ratio0.50 Sales Q/Q38.90% Oper. Margin- RSI (14)30.51 Volatility8.93% 9.26%
OptionableNo Debt/Eq0.17 EPS Q/Q65.60% Profit Margin- Rel Volume0.91 Prev Close2.04
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume79.84K Price1.87
Recom- SMA20-16.37% SMA50-30.71% SMA200-43.42% Volume72,692 Change-8.33%
Sep-10-21 08:30AM  
Aug-17-21 09:25AM  
Aug-16-21 08:30AM  
Aug-12-21 08:00AM  
Aug-11-21 10:39AM  
Jul-27-21 09:25AM  
Jul-13-21 09:15AM  
Jul-12-21 08:15AM  
Jun-02-21 10:12AM  
May-17-21 08:22AM  
May-14-21 08:30AM  
May-07-21 08:00AM  
Mar-18-21 09:00AM  
Feb-18-21 08:00AM  
Feb-04-21 08:30AM  
Jan-19-21 08:00AM  
Dec-08-20 04:15PM  
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.